Known targets — ChEMBL curated mechanism
COXFA4COXFA4L2MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3
The experimentally established mechanism targets of Me-344. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR2 | Q92731 | 9/20 | 0.36 |
| ▸ | ESR1 | P03372 | 8/20 | 0.36 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.35 |
| ▸ | ALOX12 | P18054 | 2/20 | 0.35 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | SHBG | P04278 | 1/20 | 0.33 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Me-344 SCHEMBL2713213 | 1.00 | ESR2 (0.36) | ESR2ESR1PTGS1ALOX15ALOX12 | |
| Me-344 SCHEMBL30276333 | 1.00 | ESR2 (0.36) | ESR2ESR1PTGS1ALOX15ALOX12 | |
| Me-344 SCHEMBL17965959 | 1.00 | ESR2 (0.36) | ESR2ESR1PTGS1ALOX15ALOX12 | |
| Me-344 SCHEMBL10073998 | 1.00 | ESR2 (0.36) | ESR2ESR1PTGS1ALOX15ALOX12 | |
| Me-344 SCHEMBL15312098 | 1.00 | ESR2 (0.36) | ESR2ESR1PTGS1ALOX15ALOX12 | |
| Me-344 SCHEMBL30362759 | 1.00 | ESR2 (0.36) | ESR2ESR1PTGS1ALOX15ALOX12 | |
| SCHEMBL15965356 | 0.96 | ALOX15 (0.41) | ESR2ESR1PTGS1ALOX15ALOX12 | |
| SCHEMBL17916795 | 0.96 | ALOX15 (0.41) | ESR2ESR1PTGS1ALOX15ALOX12 | |
| SCHEMBL15312298 | 0.92 | ALOX15 (0.44) | ESR2ESR1PTGS1ALOX15ALOX12 | |
| SCHEMBL301907 | 0.92 | ALOX15 (0.44) | ESR2ESR1PTGS1ALOX15ALOX12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 573 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260076969-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2026-03-19 | — | — | US | claimed |
| US-20250381202-A1 | PRODRUG KIT FOR MULTI-PRONGED CHEMOTHERAPY | ZOUNEK ALEX (DE) | 2025-12-18 | — | — | US | claimed |
| EP-4062917-B1 | CANCER TREATMENTS USING COMBINATIONS OF PI3K/AKT PATHWAY AND ERK INHIBITORS | BIOMED VALLEY DISCOVERIES INC (US) | 2025-12-03 | — | — | EP | claimed |
| US-20250336533-A1 | Methods and Systems for Evaluation of Lupus Based on Ancestry-Associated Molecular Pathways | AMPEL BIOSOLUTIONS LLC (US) | 2025-10-30 | — | — | US | claimed |
| EP-4616404-A1 | METHODS AND SYSTEMS FOR EVALUATION OF LUPUS BASED ON ANCESTRY-ASSOCIATED MOLECULAR PATHWAYS | Ampel Biosolutions, LLC (US) | 2025-09-17 | — | — | EP | claimed |
| CN-120077031-A | Prodrug kit for multitube concurrent chemotherapy | 亚历克斯·祖内克 | 2025-05-30 | — | — | CN | claimed |
| US-20250170082-A1 | HPDL INHIBITORS AND USES THEREOF | NEW YORK UNIVERSITY (US) | 2025-05-29 | — | — | US | claimed |
| EP-4551565-A1 | PRODRUG KIT FOR MULTI-PRONGED CHEMOTHERAPY | Zounek, Alex (DE) | 2025-05-14 | — | — | EP | claimed |
| WO-2025085311-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF KMT2D-DEFICIENT CANCERS | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2025-04-24 | — | — | WO | claimed |
| WO-2024102200-A9 | METHODS AND SYSTEMS FOR EVALUATION OF LUPUS BASED ON ANCESTRY-ASSOCIATED MOLECULAR PATHWAYS | AMPEL BIOSOLUTIONS, LLC (US) | 2024-10-17 | — | — | WO | claimed |
| WO-2023280175-A1 | METHODS FOR TREATING COMPLEX I DEFICIENCIES OR CANCERS BY MODULATING GRO3P BIOSYNTHESIS | NATIONAL INSTITUTE OF BIOLOGICAL SCIENCES, BEIJING (CN) | 2023-01-12 | — | — | WO | claimed |
| US-20220401579-A1 | INCLUSION COMPLEXES OF PHARMACEUTICALS AND CYCLIC OLIGOMERS | DISPERSOL TECHNOLOGIES, LLC (US) | 2022-12-22 | — | — | US | claimed |
| WO-2022170060-A1 | COMBINATION THERAPY FOR TREATING ABNORMAL CELL GROWTH | VERASTEM, INC. (US) | 2022-08-11 | — | — | WO | claimed |
| US-11390600-B2 | Crystalline forms of C21H22Cl2N4O2 | BIOMED VALLEY DISCOVERIES, INC. (US) | 2022-07-19 | — | — | US | claimed |
| CN-114746093-A | Method for treating vascular malformations | 德西费拉制药有限责任公司 | 2022-07-12 | — | — | CN | claimed |
| EP-4013417-A1 | METHODS AND COMPOSITIONS FOR TREATING VASCULAR MALFORMATIONS | Deciphera Pharmaceuticals, LLC (US) | 2022-06-22 | — | — | EP | claimed |
| WO-2022109307-A1 | TREATMENT OF KRAS MUTANT CANCERS | MEI PHARMA, INC. (US) | 2022-05-27 | — | — | WO | claimed |
| EP-3082957-B1 | CANCER TREATMENTS USING COMBINATIONS OF PI3K/AKT PATHWAY AND ERK INHIBITORS | BIOMED VALLEY DISCOVERIES INC (US) | 2022-04-06 | — | — | EP | claimed |
| EP-3969050-A1 | ANTI-CANCER NUCLEAR HORMONE RECEPTOR-TARGETING COMPOUNDS | Nuvation Bio Inc. (US) | 2022-03-23 | — | — | EP | claimed |
| US-20220040180-A1 | KITS AND METHODS FOR TREATING CANCERS | TALON THERAPEUTICS, INC. | 2022-02-10 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250381202-A1 | PRODRUG KIT FOR MULTI-PRONGED CHEMOTHERAPY | KIT, CTSL, PAICS | ESR2 4349/4885ESR1 2001/4885PTGS1 3745/4885 |
| US-20250170082-A1 | HPDL INHIBITORS AND USES THEREOF | HPGDS, AIPL1, PON1 | ESR2 4057/4885ESR1 4380/4885PTGS1 35/4885 |
| US-20220401579-A1 | INCLUSION COMPLEXES OF PHARMACEUTICALS AND CYCLIC OLIGOMERS | IAPP, PRNP, PUF60 | ESR2 4525/4885ESR1 4563/4885PTGS1 2976/4885 |
| US-20260076969-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER | ATP5ME, MT-ATP6, ATP5MK | ESR2 2174/4885ESR1 3218/4885PTGS1 1078/4885 |
| US-20220040180-A1 | KITS AND METHODS FOR TREATING CANCERS | KIT, TP53, RNASE1 | ESR2 2940/4885ESR1 3437/4885PTGS1 1918/4885 |
| US-11390600-B2 | Crystalline forms of C21H22Cl2N4O2 | CYP2F1, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CA4 | ESR2 2461/4885ESR1 3274/4885PTGS1 1324/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.